Columbus, United States
Invirsa, Inc, founded in 2016, operates at the forefront of the biotechnology and health care industries. The company's flagship product, INV-102, is a revolutionary small molecule that promotes ocular DNA repair and boosts the innate immune response to combat infection and injury.
This innovative molecule has shown significant efficacy in animal models for ocular injuries caused by sulfur mustard gas, a severe chemical weapon, making it the first drug to potentially prevent the long-term effects of such damage. With no current FDA-approved therapies available for these ocular injuries, INV-102 stands out as a promising solution.
In September 2020, Invirsa secured a substantial $29.6M award from BARDA to support the clinical journey of INV-102 through Phase 3 trials. Further bolstering its financial foundation, Invirsa received a $7.70M Series B investment in April 2023 from prominent investors including CincyTech, Rev1 Ventures, JobsOhio, and Jumpstart Ventures.
